Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK

With the US launch of the Evoke System, Saluda Medical is changing the game in spinal cord stimulation (SCS). At the North American Neuromodulation Society (NANS) Annual meeting in Las Vegas in January, researchers presented impressive 36-month data from the Company’s Evoke Study and the Company was showcasing its Evoke System for the first time on the NANS exhibit hall floor. As the first commercially available closed-loop SCS system using evoked compound action potentials (ECAPs), Evoke is unlike anything on the market. The technology automatically adjusts stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. The Company received FDA PMA for Evoke in February 2022 and announced a limited US commercial release in December 2022, calling it the first and only ‘SmartSCS” in the US.

Saluda Medical President and CEO Jim Schuermann discusses bringing Evoke System to market, the Company’s US launch and commercialization plans, the newest generation of Evoke, his vision for the future and Evoke’s potential impact on the market in an interview with SmartTRAK. Click the button below to download and read a complete transcript of the interview.

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

SmartTRAK highlights key movements in the quickly changing landscape of interventional pain management and identifies practice trends surrounding SCS, PNS, minimally invasive spine and SI Joint Fusion from the recent ASPN and INS meetings.

Strong demand for alternatives to narcotic pain management combined with an aging population and growing incidence of chronic pain continue to drive demand for interventional pain techniques. The approach to the treatment of chronic intractable pain is evolving, with a shift toward data-focused treatment optimization, growing use of digital monitoring and holistic evaluation of patient outcomes. Furthermore, increasing overlap among various devices and therapies as well as unclear boundaries between interventional pain, orthopedic and spine practices is spurring physicians to adopt collaborative approaches to patient care.

Among the many timely topics covered in this comprehensive Market Outlook article "Pain Intervention: A Market of Moving Targets", which can be downloaded in its entirety here, are:

Michael Chen, MD, the 2022 President of the Society of Neurointerventional Surgery (SNIS) and a neurointerventionalist at Rush University Medical Center in Chicago, discusses advances in stroke care research and innovation in an interview with   SmartTRAK at the SNIS 19 ^th Annual meeting held in Toronto, Ontario, Canada July 25-29, 2022. 

Adam Hattan, VP of Marketing for Route 92 Medical, discusses the Company, its novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at SNIS 2022.

Amid a growing number of me-too devices, one company that is differentiating itself in the market for stroke thrombectomy is Route 92 Medical (R92). Adam Hattan, R92’s vice president of marketing, discusses R92’s novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th Annual Meeting held in Toronto, Canada July 25-29, 2022.

To find out more about R92, its Monopoint operating platform and the Company’s strategies for growth, click on the following video recorded live at SNIS 2022.  (10:13 min). A link to download a transcript of the interview is also provided below.

Improved aspiration systems, large-bore catheters, balloon-guide catheters and radial access top the list of neurovascular device trends that will continue in 2022.

In the market for mechanical thrombectomy devices, the pace of innovation shows no signs of slowing down in 2022. Manufacturers are designing neurointerventional devices with an eye toward improving first-pass effect, recanalization rates and reducing procedure times to ultimately improve patient outcomes In this article, SmartTRAK highlights recent trends in neurovascular technologies, including variable pressure aspiration systems, large-bore catheters (LBCs), balloon-guide catheters (BGCs) and radial access, as key areas of innovation moving into 2022.

Along with the recent trends in neurovascular technologies, the following topics are covered in detail in this article, which is available for download here:

• Outgrowing Standard Aspiration Systems
• Continued Trend Toward Large-Bore Catheters for Access and Aspiration
• New Designs and Applications for Balloon-Guide Catheters
• Increasing Competition in Radial Access